Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00223964 · ClinicalTrials.gov registry record · Phase 4

Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients

A Phase 4 study of Anemia, sponsored by Watson Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
59
Enrollment target
20
Study locations

NCT00223964: Completed Phase 4 study of Anemia, sponsored by Watson Pharmaceuticals.

NCT00223964 is a Phase 4 study of Anemia that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 59 participants, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00223964, a Phase 4 study of Anemia, has completed, sponsored by Watson Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
59 participants
Enrollment target
20
Study locations

Study Summary

This was a multi-center study in iron-deficient pediatric hemodialysis patients, whose legal guardian had provided signed informed consent and satisfied the inclusion and exclusion criteria.

Conditions Studied

Interventions

  • DRUG Ferrlecit (sodium ferric gluconate complex in sucrose injection)

Study Locations (20)

Other

  • - Aruascalientes
  • - Mexico City
  • - Bialystok
  • - Gdansk
  • - Krakow
  • - Lodz
  • - Lublin
  • - Szczecin
  • - Torum
  • - Wroclaw
  • - Zabrze
  • - Bashkortostan

California

  • - Los Angeles
  • - San Diego
  • - Stanford

Alabama

  • - Birmingham

Massachusetts

  • - Boston

Missouri

  • - Kansas City

New York

  • - The Bronx

Washington

  • - Seattle

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2003-06
Phase Phase 4
Watson Pharmaceuticals

28 total trials

What the finished NCT00223964 record still lists

NCT00223964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 427-participant average among 72 other Anemia trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Anemia appearing as the primary indexed condition, and to 1 intervention - of which Ferrlecit (sodium ferric gluconate complex in sucrose injection) is the first listed.

NCT00223964 names 20 study sites across 7 states, led by Other, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT00223964 about?

NCT00223964 is a clinical study titled "Study of the Efficacy of Two Doses of Ferrlecit in the Treatment of Iron Deficiency in Pediatric Hemodialysis Patients". This was a multi-center study in iron-deficient pediatric hemodialysis patients, whose legal guardian had provided signed informed consent and satisfied the inclusion and exclusion criteria.

What is the current status of trial NCT00223964?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2003-06.

What conditions does trial NCT00223964 study?

This clinical trial studies the following conditions: Anemia.

What interventions are being tested in trial NCT00223964?

The interventions under investigation include: Ferrlecit (sodium ferric gluconate complex in sucrose injection) (DRUG).

Who is sponsoring clinical trial NCT00223964?

This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00223964 being conducted?

This trial has 20 study locations across Alabama, California, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00223964's enrollment target sits among peer trials

59 55th of 72 higher than 18 of 72 other Anemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03801083 · 59 participants · Phase 2

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

  • NCT04332367 · 59 participants · Phase 2

    Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

  • NCT05489575 · 59 participants · NA

    CPAP for the Treatment of Supine Hypertension

  • NCT06721689 · 59 participants · Phase 1

    PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00223964, the US trial registry maintained by the National Library of Medicine. NCT00223964 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.